ASCO GUIDELINES Bundle

Systemic Therapy for Melanoma

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475505

Contents of this Issue

Navigation

Page 6 of 7

Table 2. Reasonable dose/schedule details for recommended regimens – Unresectable/Metastatic Disease Regimen (Recommendation #) Dosing Schedules (Source) Ipilimumab plus nivolumab followed by nivolumab until disease progression (3.1, 3.2) Ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg every 2 weeks, all by intravenous infusion (Checkmate 067) Ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 3 weeks for 4 doses, followed by nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks all by intravenous infusion (FDA prescribing information) Nivolumab (3.1, 3.2) Nivolumab 3 mg/kg every 2 weeks by intravenous infusion (Checkmate 067) Nivolumab 240 mg every 2 weeks (US FDA Approved) Nivolumab 480 mg every 4 weeks (US FDA Approved) Pembrolizumab (3.1, 3.2) Pembrolizumab 10 mg/kg every 2 weeks or every 3 weeks by intravenous infusion (Keynote 006) Pembrolizumab 2 mg/kg every 3 weeks by intravenous infusion (Keynote 002) Pembrolizumab 200 mg every 3 weeks (US FDA approved) Pembrolizumab 400 mg every 6 weeks (EU EMA approved [based on Lala et al 2018]) Vemurafenib plus cobimetinib (2.2) Vemurafenib 960 mg orally twice daily without pause plus cobimetinib 60 mg orally once daily in a cycle of 21 days with 7 days off. (CoBRIM) Dabrafenib plus trametinib (3.2) Dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily. (COMBI-v) Encorafenib plus binimetinib (3.2) Encorafenib 450 mg orally once daily plus binimetinib 45 mg orally twice daily (COLUMBUS) NOTE: ese were doses/schedules considered reasonable at the time of publication of this guideline. Additional doses and schedules may have been approved at the time of reading.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Systemic Therapy for Melanoma